The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer

医学 乳腺癌 新辅助治疗 肿瘤科 内科学 癌症 雌激素受体 纳特 疾病 阶段(地层学) 计算机网络 计算机科学 生物 古生物学
作者
Laura M. Spring,Yael Bar,Steven J. Isakoff
出处
期刊:Journal of The National Comprehensive Cancer Network 卷期号:20 (6): 723-734 被引量:46
标识
DOI:10.6004/jnccn.2022.7016
摘要

The role of neoadjuvant therapy (NAT) for localized breast cancer has evolved tremendously over the past several years. Currently, NAT is the preferred option for high-risk early triple-negative (TN) and HER2-positive (HER2+) breast cancers and is indicated for some estrogen receptor–positive (ER+) breast cancers. In addition to traditional absolute indications for NAT, relative indications such as the assessment of outcomes at the time of surgery and guidance of treatment escalation and de-escalation have greatly evolved in recent years. Pathologic complete response (pCR) and the Residual Cancer Burden (RCB) index are highly prognostic for disease recurrence and survival, mainly in patients with TN or HER2+ disease. Furthermore, post-NAT escalation strategies have been shown to improve long-term outcomes of patients who do not achieve pCR. Additionally, by allowing the direct assessment of drug effect on the tumor, the neoadjuvant setting has become an attractive setting for the exploration of novel agents and the identification of predictive biomarkers. Neoadjuvant trial design has also evolved, using adaptive treatment approaches that enable treatment de-escalation or escalation based on response. However, despite multiple practice-changing neoadjuvant trials and the addition of various new agents to the neoadjuvant setting for early breast cancer, many key questions remain. For example, patient selection for neoadjuvant immunotherapy in TN breast cancer, de-escalation methods in HER2+ breast cancer, and the use of gene expression profiles to guide NAT recommendations in ER+ breast cancer. This article reviews the current approach for NAT in localized breast cancer as well as evolving NAT strategies, the key remaining challenges, and the ongoing work in the field.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
meng发布了新的文献求助10
刚刚
研友_VZG7GZ应助魅雪霓采纳,获得10
1秒前
斯文明杰发布了新的文献求助10
1秒前
江峰驳回了张雷应助
2秒前
Orange应助mjj采纳,获得10
2秒前
3秒前
winter发布了新的文献求助20
3秒前
NexusExplorer应助超靓诺言采纳,获得10
4秒前
monica发布了新的文献求助10
4秒前
4秒前
斯文败类应助eff采纳,获得10
4秒前
Ava应助humblelucas采纳,获得10
5秒前
Avert.完成签到 ,获得积分10
5秒前
ding应助Mila采纳,获得10
6秒前
DijiaXu应助chong0919采纳,获得10
6秒前
飞天走地的香辣鱿鱼完成签到,获得积分10
6秒前
北鱼完成签到 ,获得积分10
6秒前
Kay完成签到,获得积分10
6秒前
南宫子骞完成签到,获得积分10
6秒前
7秒前
7秒前
汪汪队路马完成签到,获得积分10
7秒前
7秒前
9秒前
meng完成签到,获得积分10
9秒前
大模型应助生动的翠容采纳,获得30
10秒前
bkagyin应助李昕123采纳,获得10
11秒前
凉笙墨染完成签到,获得积分10
11秒前
11秒前
kathy完成签到,获得积分10
11秒前
TianxingLiu发布了新的文献求助10
11秒前
12秒前
茴茴发布了新的文献求助10
12秒前
fantianhui完成签到,获得积分10
12秒前
12秒前
可爱的函函应助kaka采纳,获得10
12秒前
13秒前
13秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3971277
求助须知:如何正确求助?哪些是违规求助? 3515939
关于积分的说明 11180280
捐赠科研通 3251061
什么是DOI,文献DOI怎么找? 1795664
邀请新用户注册赠送积分活动 875937
科研通“疑难数据库(出版商)”最低求助积分说明 805209